RAPT Therapeutics (NASDAQ:RAPT) Releases Quarterly Earnings Results, Misses Estimates By $0.69 EPS

RAPT Therapeutics (NASDAQ:RAPT) posted its quarterly earnings results on Thursday. The company reported ($1.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.69), Zacks reports.

RAPT Therapeutics Price Performance

RAPT Therapeutics stock traded up $0.03 during midday trading on Thursday, hitting $1.16. The company’s stock had a trading volume of 115,850 shares, compared to its average volume of 826,612. The company has a market cap of $40.38 million, a price-to-earnings ratio of -0.42 and a beta of -0.31. RAPT Therapeutics has a 1-year low of $0.79 and a 1-year high of $10.05. The company has a 50-day moving average price of $1.27 and a two-hundred day moving average price of $1.57.

Analyst Ratings Changes

RAPT has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. lowered RAPT Therapeutics from a “neutral” rating to an “underweight” rating in a report on Monday, November 11th. Piper Sandler downgraded shares of RAPT Therapeutics from an “overweight” rating to a “neutral” rating and decreased their price objective for the company from $8.00 to $2.00 in a report on Monday, November 11th. Stifel Nicolaus restated a “hold” rating and set a $2.00 target price (down previously from $7.00) on shares of RAPT Therapeutics in a research note on Wednesday, November 13th. Wells Fargo & Company decreased their price target on shares of RAPT Therapeutics from $17.00 to $4.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 12th. Finally, HC Wainwright upgraded shares of RAPT Therapeutics from a “neutral” rating to a “buy” rating and set a $10.00 price objective for the company in a research report on Thursday, December 26th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $5.29.

RAPT Therapeutics Company Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.